BARNETT INTERNATIONAL HOLDS FIRST LIVE INTERNET-BASED TRAINING SEMINAR FOR CLINICAL RESEARCH PROFESSIONALS
MEDIA, PA, March 22, 2000 — Barnett International Corporation, a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), announced today the successful completion of the first ever Interactive Internet Training (IIT) for pharmaceutical clinical research professionals. The three-day "Clinical Research Coordinator Training" program allowed participants from across the U.S. to experience virtually the same curriculum that Barnett offers in its in-person training program, without travel, lodging and meal expenditures. Participants from nine states participated in the training session from work and home offices.
Barnett's Internet Training utilizes technology to facilitate training sessions so that students and instructors from different locations and time zones can participate. With globalization, new training models emphasizing time, cost and travel savings are extremely attractive from an employer's perspective. This program facilitates the attendance of many professionals who, due to time and budget constraints, could not otherwise participate.
"This is an exciting step forward in the clinical research training arena," said John Snodgrass, Vice President of Training at Barnett. "Everything that can be accomplished in an in-person meeting can be addressed in this forum. Since it is live and interactive, the leader and the audience can participate and communicate during the session."
Barnett plans to expand the use of this technology to facilitate other forums for clinical research professionals, including investigator meetings, clinical trial protocol development and review meetings.
Barnett International is a recognized industry leader in pharmaceutical consulting, education and training, specializing in such areas as technology, performance benchmarking, clinical training, knowledge management, industry conferences, and the publication of drug development texts and journals.
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that accelerate time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. The Company's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 43 locations throughout 29 countries around the world, and has approximately 4,600 employees.
This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future growth, financial performance, operations, client relationships, and customer demand. The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Factors that might cause such a difference include, but are not limited to, risks associated with: the loss or delay of large contracts; the Company's dependence on certain industries and clients and its ability to retain and expand its client relationships; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses; government regulation of certain industries and clients; competition and consolidation within the industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. These factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 1999.